Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Endocrinology and Metabolic Disease | 2 |
Neoplasms | 2 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
AAV based gene therapy | 6 |
Gene therapy | 1 |
Target |
Mechanism adrenergic receptor antagonists |
Originator Org. |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date30 Jan 1952 |
Mechanism PTGFR agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism APE1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator Opus Genetics, Inc. [+1] |
Start Date15 Jun 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Latanoprost/Phentolamine ( PTGFR x adrenergic receptor ) | Mydriasis More | NDA/BLA |
Phentolamine Mesylate ( adrenergic receptor ) | Night Blindness More | Phase 3 |
OPGx-BEST1 ( BEST1 ) | Vitelliform Macular Dystrophy More | Phase 2 Clinical |
RX-5902 ( DDX5 ) | Breast Cancer More | Phase 2 |
APX3330 ( APE1 ) | Proliferative retinopathy with diabetes mellitus More | Phase 2 |